What the Research Says
Black Cohosh is well-supported by clinical evidence for alleviating menopausal symptoms. A Cochrane review by Leach and Moore (2012) analyzed 16 randomized controlled trials, concluding that black cohosh significantly reduces vasomotor symptoms compared to placebo, despite variability in study quality. Osmers et al. (2005) conducted a rigorous RCT involving 304 menopausal women, demonstrating that isopropanolic black cohosh extract (iCR), the basis of Remifemin, improved menopausal complaints over 12 weeks.
Recent studies further validate these findings. Sadahiro et al. (2023) conducted a meta-analysis of 22 studies involving 2,310 women, confirming that black cohosh extracts significantly improved overall menopausal symptoms, hot flashes, and somatic symptoms compared to placebo. Castelo-Branco et al. (2021) reviewed and analyzed data from 43 studies, reinforcing the efficacy of isopropanolic black cohosh extract in managing menopausal symptoms.
Regarding safety, Naser et al. (2011) performed a meta-analysis of five randomized controlled trials involving 1,117 women, finding no evidence of hepatotoxicity associated with isopropanolic black cohosh extract. Both the American Herbal Products Association and the European Medicines Agency have concluded that hepatotoxicity risk is very low when using standardized extracts.
These studies collectively highlight the efficacy and safety of black cohosh in managing menopausal symptoms, supported by rigorous clinical evidence.



